Fulgent Genetics Inc. (FLGT) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, FLGT scores 35 out of 100 with a letter grade of D- and a verdict label of "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 5/20 (ROIC of -6.8% and FCF yield of -20.82%), Whale 13F Flow at 12/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8/20 (Beta of 1.0 and sector sensitivity), and Forensic Balance Sheet at 7/20 (Altman Z-Score of 4.44, Piotroski F-Score of 3/9, Debt/Equity of 0.5). For a prospective investor, the weakest pillars are cash generation and insider conviction. Negative ROIC and deeply negative FCF yield indicate the business is not currently converting capital into cash returns, so any upside case depends on a future operating turnaround that the source data does not quantify. The strongest pillar relative to its weight is the Forensic Balance Sheet, where the Altman Z-Score and a Debt/Equity of 0.5 suggest limited near-term solvency pressure, though a Piotroski F-Score of 3/9 signals weak fundamental quality. Valuation tradeoffs are difficult to assess because P/E and EV/EBITDA are not available in source data. Upside drivers would need to come from revenue recovery and margin repair; the 52-week range of $13.46 - $31.04 and the current price of $21.68 show a wide trading band that reflects volatility rather than a stable earnings base.

Fulgent Genetics Inc. is a NASDAQ-listed issuer classified under the Health Care sector and the Medical Specialities industry, per the profile section. The source data does not describe its specific products, customer base, or revenue model. Market capitalization is listed at $0.6B per the profile. Revenue scale is reported in the SEC financials, with FY 2025 revenue of $322.7M.

Per the SEC financials, the company reported operating losses in all three periods, with FY 2025 operating income of $-91.1M. Per the market data, the gross margin is 40.6%, the operating margin is -28.2%, and the net margin is -18.8%, with ROIC at -6.8%. Per the Roarable RQD rating, the Altman Z-Score is 4.44 and the Piotroski F-Score is 3/9, with Debt/Equity at 0.5. Cash declined from $55.1M in FY 2024 to $50.2M in FY 2025 while FCF was negative in both years.

Per the recent news and catalysts section, the most recent items are MarketBeat and Yahoo Finance reports noting a 6.5% share decline and a break below the 50-day moving average, both flagged YELLOW. A scheduled event is the announcement of third quarter 2026 financial results on Thursday, November 5, 2026. Form 4 filings for Chief Scientific Officer Hanlin Gao (filed for October 26) also appear in the wire. Risk watch items include the share price weakness and the negative FCF trend. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE with no butterfly links and no proprietary signals.

• What are the company's core products and revenue segments, given that the source describes only the sector and industry classification?
• What is the reported EPS and forward earnings expectation, since P/E and EPS fields are unavailable?
• What is the debt balance behind the stated Debt/Equity ratio of 0.5, since the debt field is N/A across all periods?
• What is driving the FY 2025 FCF decline to $-124.2M, and what capital expenditure or working capital factors contributed?
• What are the results and guidance from the upcoming third quarter 2026 report, and how will they affect the operating loss trend?